Related Experiment Video
Updated: May 28, 2026
03:11
Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice
Published on: June 7, 2024
Vanadium-Doped Bioactive Glass-Modified GelMA/CMCS/HA Injectable Hydrogel for Osteosarcoma Postoperative Therapy and
Dazhong Jin1, Miaomiao He1, Guangfu Yin1
1College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.
Materials (Basel, Switzerland)
|May 27, 2026
Summary
Researchers developed an injectable hydrogel for osteosarcoma bone defects. This GelMA/CMCS/HA hydrogel promotes bone regeneration and suppresses tumors, offering a dual therapeutic solution.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Oncology
Background:
- Osteosarcoma surgery often leaves irregular bone defects, necessitating effective postoperative management for bone regeneration and tumor recurrence prevention.
- Current treatments face challenges in adapting to complex defect geometries and ensuring stable fixation.
- Developing multifunctional materials is crucial for addressing both bone defect repair and tumor suppression.
Purpose of the Study:
- To develop a multifunctional, injectable, and rapidly photo-curable hydrogel for treating osteosarcoma-associated bone defects.
- To evaluate the hydrogel's capacity for bone regeneration and its antitumor efficacy.
- To investigate the synergistic effects of its components and vanadium-doped mesoporous bioactive glass (VMBG) on the bone microenvironment.
Main Methods:
- Fabrication of a hydrogel composite using gelatin methacryloyl (GelMA), carboxymethyl chitosan (CMCS), hyaluronic acid (HA), and VMBG.
- Assessment of injectability and rapid photocurability for defect adaptation and fixation.
- In vitro evaluation of antitumor activity via reactive oxygen species (ROS) generation.
- In vitro assessment of osteogenic potential by measuring alkaline phosphatase (ALP) activity and osteogenic marker expression.
Main Results:
- The GelMA/CMCS/HA hydrogel demonstrated excellent injectability and rapid photocurability, enabling seamless filling of irregular defects.
- The VMBG component exhibited potent antitumor efficacy through ROS generation.
- The hydrogel formulation significantly enhanced osteogenic activity, promoting bone regeneration.
- CMCS and HA components contributed to defect healing and improved scaffold bioactivity, respectively.
Conclusions:
- A novel multifunctional injectable hydrogel (GelMA/CMCS/HA/VMBG) was successfully developed for osteosarcoma bone defect treatment.
- The hydrogel possesses dual therapeutic functions: promoting bone regeneration and suppressing tumor recurrence.
- This advanced biomaterial offers a promising strategy for improving clinical outcomes in osteosarcoma patients.
